178 related articles for article (PubMed ID: 34218288)
1. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
2. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
3. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
4. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
5. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
8. Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder.
Paner GP; Cox RM; Richards K; Akki A; Gokden N; Lopez-Beltran A; Krausz T; McKenney JK; Steinberg GD
Am J Surg Pathol; 2014 Sep; 38(9):1251-9. PubMed ID: 25133708
[TBL] [Abstract][Full Text] [Related]
9. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
12. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
[TBL] [Abstract][Full Text] [Related]
13. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
[TBL] [Abstract][Full Text] [Related]
14. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma.
Cox R; Epstein JI
Am J Surg Pathol; 2011 Sep; 35(9):1337-42. PubMed ID: 21836490
[TBL] [Abstract][Full Text] [Related]
15. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
Fichtenbaum EJ; Marsh WL; Zynger DL
Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
17. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
Li J; Lu S; Lombardo K; Monahan R; Amin A
Hum Pathol; 2016 Sep; 55():17-23. PubMed ID: 27137986
[TBL] [Abstract][Full Text] [Related]
18. Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma.
Miyamoto H; Sharma RB; Illei PB; Epstein JI
Am J Surg Pathol; 2010 Mar; 34(3):418-22. PubMed ID: 20154589
[TBL] [Abstract][Full Text] [Related]
19. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
20. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
